TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage II, III,or IV lung or pancreatic cancer~* Fair, poor, or very poor appetite~* Cancer associated anorexia/cachexia~* Weight loss perceived to be associated with diminished appetite~* Eastern Cooperative Oncology Group Performance score of 0, 1, 2~* Life expectancy \>3 months~* Alert and mentally competent~* Women of child-bearing potential required to use an adequate and reliable method of contraception. Post-menopausal women have to have been so for at least 1 year~* Screening laboratory values must not be clinically significant (some exceptions per protocol)~Exclusion Criteria:~* Brain, or head and neck metastases that may interfere with food consumption~* AIDS-related wasting~* Radiation therapy to the head and neck, abdomen, or pelvis within past 6 weeks, or anticipated during course of the study such that the result may interfere with food consumption~* Conditions that interfere with oral intake, or ability to swallow~* Absence of a normally functioning gut~* Mechanical obstruction of the alimentary or biliary tract, or malabsorption syndrome~* Intractable or frequent vomiting that regularly interfere with eating~* Clinically significant diarrhea~* History of recurrent thromboembolic events, a thromboembolic event in past 3 months, or long-term anticoagulation treatment for thromboembolism~* Uncontrolled diabetes mellitus, or symptomatic hypoadrenalism~* Poorly controlled hypertension, or congestive heart failure~* Pregnant/lactating females~* Use within past 30 days of an appetite stimulant~* Use within past week, or planned use during the study of parenteral nutrition or tube feedings~* Chronic use of steroids within past 3 months (intermittent short-term use allowed)~* Current use of or not willing to abstain from using illicit substances~* Allergy, hypersensitivity, or contraindication to megestrol acetate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Megestrol acetate concentrated suspension 110 mg/mL
- 2 (Type: PLACEBO_COMPARATOR): Placebo suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GVAX vs. Placebo for MDS/AML After Allo HSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* AML, CMML-with excess blasts, MDS-RAEB not in remission prior to leukemia cell harvest~* HLA 8/8 or 7/8 matched related or unrelated donor available~* ECOG performance status of 0-2~* Suitable candidate for myeloablative or reduced intensity conditioning allogeneic HSCT using PBSC or marrow as stem cell resource~* Normal organ function~Exclusion Criteria:~* Pregnant or breastfeeding~* Leukemia with active CNS involvement~* Positive HIV or HTLV-1 serology~* History of allergic reactions to compounds of similar chemical or biologic composition to GM-CSF~* Uncontrolled intercurrent illness~* History of different malignancy except if disease free for at least two years or cervical cancer in situ, basal or squamous cell carcinoma of the skin diagnosed and treated within the past two years~* Prior allogeneic transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GVAX (Type: ACTIVE_COMPARATOR): GVAX vaccine~Participants in the GVAX vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. GVAX arm participants meeting criteria to begin vaccinations will be administered the GVAX vaccine at established study time points.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo vaccine~Participants in the Placebo vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. Placebo vaccine arm participants meeting criteria to begin vaccinations will be administered the placebo vaccine at established study time points.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration (FNA) EUS-FNA of Solid Pancreatic Mass Lesions Using a Novel Corkscrew Technique: a Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* In-patients and out-patients between the age of 18 and 90 years with solid pancreatic masses presenting for EUS-Fine Needle Aspiration (FNTA)~Exclusion Criteria:~* Uncorrectable coagulopathy (INR \> 1.5)~* Uncorrectable thrombocytopenia (platelet \< 50,000)~* Uncooperative patients~* Pregnant women (women of childbearing age will undergo urine pregnancy testing, which is routine for all endoscopic procedures)~* Refusal to consent form~* Prior negative FNTA~* In situ metallic biliary stents~* Predominantly cystic lesions~* Inaccessible lesions to EUS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Pancreatic mass (Type: EXPERIMENTAL): Patients with pancreatic mass presenting for EUS-FNA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of NOTES (Natural Orifice Translumenal Endoscopic Surgery) PEG Rescue

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: Patients must meet ALL of the following criteria~* For prospective candidates, an initial attempt to pass a balloon tipped foley catheter through the external cutaneous tract into the stomach will be performed. It will then be followed by radiographic contrast study to evaluate for extravasation of contrast into the peritoneal cavity. If contrast is extravasated, this will be potential candidate for inclusion. If the foley catheter is unable to be passed through the cutaneous tract, that will also be considered someone for inclusion as this patient will still require an operative confirmation of the patency of the gastrotomy.~* For retrospective candidates, intra-operative confirmation of dislodged tube as reported in the medical record.~* The patient must demonstrate pre-operative hemodynamic and respiratory stability~* No overwhelming medical co-morbidities prohibitive of surgery~* Subject is 18 years of age or older~* Subject or subject's legal decision-making proxy agrees to participate, fully understands and signs the informed consent form~Exclusion Criteria: Patients must not meet ANY of the following criteria:~* Esophageal stricture prohibiting passage of an endoscope~* Any contraindication to surgery~* Pregnancy or actively breastfeeding women~* Evidence of active bowel obstruction~* Synchronous acute abdominal pathology warranting incision-based surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- NOTES PEG Rescue (Type: EXPERIMENTAL): A new way of performing surgery is called Natural Orifice Translumenal Endoscopic Surgery, or NOTES, for short. NOTES may allow surgeons to perform abdominal surgery without any skin incisions. By using natural openings in the body, like the mouth, surgeons can enter the stomach with a tube instead of the traditional method of making an incision in the skin of the abdomen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of TCC Followed by MBCT and Predictive Factors (Genetic, Clinical and Cognitive) Response

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18-65 years~* Men and women~* Addressed to the CBT unit of the Clinique des Maladies Mentales et de l'Encéphale - CMME- (Sainte Anne Hospital)~* Having a bipolar I or II disorder (224 patients) or eating disorder (224 patients) : bulimia or discorder of use alcohol or gambling (224 patients)~* mood stabilizer treatment for more than six months, for bipolar patients~* Understanding and speaking French fluently~* Patient agreeing to participate and signing the consent form~Exclusion Criteria:~* Age \<18 or\> 65~* current manic, hypomanic, or depressive episode for bipolar patients~* Score on the Hamilton Depression Rating Scale - HDRS greater than or equal to 16~* Score on the Mania Rating Scale - MRS higher or equal to 6 for bipolar patients~* Schizophrenic disorder~* Severe somatic pathology (cancer, heart, kidney or respiratory failure, central neurological disorder), scalable, or are likely to be life-threatening in a period of less than one year~* Refusal of a mood stabilizer treatment for bipolar patients~* Inability to respond to assessment (eg failure or deterioration of mental ability.)~* No affiliation to a social security scheme~* Private topics of liberty by judicial or administrative decision~* Pregnant women~For bipolar patients, the presence of rapid cycling, family history of bipolar disorder, comorbid Axis I and II disorders, protective measures (curatorship or guardianship) are not exclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- bipolar disorder (Type: EXPERIMENTAL): Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT
- anxious disorders (Type: EXPERIMENTAL): Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT
- alcohol disorder (Type: EXPERIMENTAL): Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Is a Smartphone Application Effective as an Oral Medication Adherence Aid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females at least 18 years of age~* Provide informed consent~* Prescribed an oral medication indicated for hypertension, diabetes, or dyslipidemia during 12 weeks pre-enrollment~* Own a smartphone (Android or iOS) with unlimited text messaging, email access, and app store access~* Oral confirmation that the subject has not previously used a medication adherence app~* Able to consult with a pharmacy or medical student during the recruitment process for purposes of consent, data collection, and/or medication reconciliation, and/or MyMedSchedule registration~Exclusion Criteria:~* Severely impaired vision~* Reside in a nursing home~* Non-ambulatory/bedridden~* Not fluent in English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Care (Type: NO_INTERVENTION): The control group will not use the medication adherence app
- Medication Adherence Smartphone App (Type: EXPERIMENTAL): The experimental group will receive the medication adherence app on their smartphone and will have their entire outpatient medication list pushed to the application. Text message reminders will be sent to their phones at the appropriate times.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Automated MEdical Record Driven Implantable CArdioverter-defibrillator Heart Failure Trial (AMERICA-HF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Left Ventricular Ejection Fraction ≤ 35% on transthoracic echocardiogram~* One of the following ICD-9 HF diagnostic codes 398.91, 428.0, 428.1, 428.2x, 428.3x, 428.4x, 428.9~Exclusion Criteria:~* Pregnancy~* Inability to speak English~* Inability to provide verbal consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Registry (Type: PLACEBO_COMPARATOR): Patients randomized to the registry arm will be followed per usual standard of care by their primary providers. Those providers may refer to subspecialty HF or electrophysiology care as they see fit.
- Intervention (Type: EXPERIMENTAL): Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology with recommendations to consider those therapies that are not in compliance with guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is 18 through 70 years of age.~* Patient has moderate to severe non-malignant chronic pain.~* Patient is opioid-tolerant, requires treatment with chronic opioids and is currently taking a dose of 50 mcg/hr transdermal fentanyl for the treatment of chronic pain. Patient must have been taking this dose for at least 2 weeks.~* Patient must be experiencing 1 to 4 episodes of target breakthrough pain (breakthrough pain that is related to the patient's chronic pain condition) a day while taking a dose of 50 mcg/hr transdermal fentanyl.~Exclusion Criteria:~* Patient has active cancer.~* Patient has a history of substance abuse or has a substance abuse disorder.~* Patient is pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 50 mcg/hr matrix fentanyl patch (Type: EXPERIMENTAL): active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)
- Placebo Patch (Type: PLACEBO_COMPARATOR): placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with imaging findings consistent with renal cell carcinoma~* Deemed medically inoperable per urology evaluation~* Tumor size \>4cm in largest dimension~* ECOG performance status of \<2~* Signed informed consent document(s)~* Patients with metastatic disease will not be excluded~Exclusion Criteria:~* Patients who fail MRI screening~* Pregnant or nursing women~* History of prior radiation therapy to the upper abdomen~* History of invasive cancer in the last 3 years (except for appropriately treated low-rist prostate cancer, treated non-melanoma/melanoma skin cancer, appropriately treated ductal carcinoma in situ or early stage invasive carcinoma of breast and appropriately treated in-situ/early stage cervical/endometrial cancer)~* Treatment with a non-approved or investigational drug within 28 days of study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy & Microwave Ablation (Type: EXPERIMENTAL): 3+3 dose-escalation wherein three dose levels of stereotactic body radiation therapy (SBRT) would be evaluated:~1. Dose level I: 6 Gy x 5 fractions~2. Dose level II: 8 Gy x 5 fractions~3. Dose level III: 10 Gy x 5 fractions~Radiation treatments will be delivered two to three times a week, with five fractions completed over two weeks.~Four to six weeks after radiation treatment, patients will undergo repeat CT or MRI imaging to assess tumor response and suitability for microwave ablations.~Eight weeks after the conclusion of SBRT, patients will undergo microwave ablation (approximately 12 weeks after registration).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patients with a lower risk MDS (LOW or INT-1 according to IPSS)~* Red blood cell transfusion dependency of at least 4 Units/8 weeks.~* Not responding to Erythropoietin stimulating agents (ESA) or having a low chance to do so~* Age-adjusted normal cardiac, kidney, liver function~Key Exclusion Criteria:~* Concomitant use of ESA~* Concomitant use of any other investigational drug~* Other malignancy that is not in remission for at least 1 year~* Platelet Count \< 75 x 109/L~* Impaired cardiac function or clinically significant cardiac diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LBH589 (Type: EXPERIMENTAL): During the core phase, all participants received oral LBH589 40 mg (30 mg after a protocol amendment) for 4 months. During the randomization phase, participants with hematological improvement of the erythropoetic system (HI-E) and participants with stable disease, who were randomized to single agent LBH589, continued on single agent LBH589 40mg/30mg for an additional 4 months.
- LBH589 + Epoetin Alfa (Type: EXPERIMENTAL): During the randomized phase, participants randomized to LBH589 + Epoetin Alfa (ESA) received oral LBH589 40mg/30mg + ESA 30000 international units (IU)/week injected subcutaneously for 4 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving once daily dosing of methylprednisolone or prednisone in a dose of 10 mg/day or greater~* Hyperglycemic (Glucose level \> 126 mg/dL)~* Diabetic and nondiabetic patients~* Expected duration of hospital stay and time on steroids \>= 3 days~* Patient of appropriate caregiver able to give Informed Consent~Exclusion Criteria:~* Patients with 2 or more doses of methylprednisolone/prednisone per day~* Steroids other than methylprednisolone or prednisone~* Pregnancy~* estimated glomerular filtration rate (eGFR) \< 45 ml/min/1.73m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NPH Insulin (Type: EXPERIMENTAL): NPH will be given at the time of steroid administration to the patient in addition to standard basal/bolus insulin the patient may be receiving in the following doses:~Prednisone Dose (mg/day) - NPH dose (U=Units): 10-20 mg/day - 1.2U (units)/mg; 21-40 mg/day - 0.6U/mg; 41-60 mg/day - 0.45U/mg; 61-80 mg/day - 0.3U/mg; \>80 mg/day - no additional NPH. Note that the amounts of NPH are added to each other for the various prednisone doses. For example, a dose of 75 mg/day of prednisone would come out to be (1.2U x 20mg = 24U) + (0.6U x 20mg = 12U) + (0.45U x 20mg = 9U) + 0.3U x 15 mg = 4.5U) for a total of 24 + 12 + 9 + 4.5 = 49.5U of NPH for 75 mg of prednisone.
- Basal/Bolus Insulin (Type: ACTIVE_COMPARATOR): Basal insulin (glargine) and Bolus insulin (insulin aspart) will be increased (doses given in U \[units\]/kg) according to the Prednisone dose (mg/day) as follows:~Prednisone Dose (mg/day) - doses of insulin (U/kg): Prednisone 0 mg - Glargine 0.25U/kg, Bkfst Aspart 0.08U/kg, Lunch Aspart 0.08U/kg, Dinner Aspart - 0.08U/kg; Prednisone 10-20 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.15U/kg, Dinner Aspart - 0.2U/kg; Prednisone 21-40 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.2U/kg, Dinner Aspart - 0.25U/kg; Prednisone 41-60 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.25U/kg, Dinner Aspart - 0.30U/kg; Prednisone 61-80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.30U/kg, Dinner Aspart - 0.35U/kg; Prednisone \>80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.35U/kg, Dinner Aspart - 0.40U/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues